Targeting KRAS G12D has already seen some shakeout – can the next generation agents prove successful?
Standing out from the crowd – 6 ADC trends to watch out for at ESMO
In an industry littered with discontinued programs and dashed hopes, Merck is placing some contrarian…
Examining a novel IO approach in advanced CRC
The promise of RNA therapeutics has captivated the biotech world for a while, yet few have seen major…
Super power can sometimes come from unexpected sources
An emerging subniche in the ADC space
A look at which TCEs induce a balanced KA-Pow Effect
Trials and tribulations associated with IO agents in solid tumours
Finding pearls before swine
For decades, p53 – the ‘guardian of the genome’ – has been oncology’s great white shark: a…
How to drug a previously intractable target
How PDOs are rising in prominence for future cancer drug approvals
Bridging the gaps in ADCs and TPD at AACR25
Three is a magic number – except when it isn’t. Trispecific antibodies are one of the emerging stars…
A smorgasbord of riches with new agents, combinations, and targets!
Digging into the details of some up and coming new agents showcased in Chicago
Will this niche rise to the occasion or sink into obscurity?
Five intriguing abstracts which stood out for different reasons
AACR 2025 is in Chicago – it’s time for our first impressions from the Windy City abstracts. The…
